Anthrax antigen induces antibodies raised against PA that may contribute to protection by neutralizing the activities of the cytotoxic lethal toxin and edema toxin of Bacillus anthracis.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC Group | Classification | |
|---|---|---|
| J07AC01 | Anthrax antigen | J Antiinfectives for systemic use → J07 Vaccines → J07A Bacterial vaccines → J07AC Anthrax vaccines |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Document | Type | Information Source | |
|---|---|---|---|
| BIOTHRAX Suspension for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
Anthrax antigen is an active ingredient of these brands:
Poland (PL)
Singapore (SG)
United Kingdom (UK)
United States (US)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.